All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50]
GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86]
0.65 [0.21 ; 2.01 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 2 0% 784 moderate not evaluable deathsdetailed results GS-US-540-5773 (Goldman), 2020 0.73 [0.37; 1.44]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
0.70 [0.39 ; 1.26 ] GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 0% 1,193 moderate not evaluable deaths (time to event analysis only)detailed results GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
0.64 [0.21 ; 1.98 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 2 0% 796 moderate not evaluable clinical improvementdetailed results GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02]
GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74]
GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49]
1.12 [0.72 ; 1.75 ] GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 79% 1,193 moderate not evaluable clinical improvement (14-day)detailed results GS-US-540-5773 (Goldman), 2020 1.53 [1.02; 2.29]
GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47]
GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44]
1.56 [1.21 ; 1.99 ] GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 0% 1,181 moderate not evaluable clinical improvement (28-day)detailed results GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42]
GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17]
1.81 [1.19 ; 2.76 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 2 0% 784 moderate not evaluable clinical improvement (7-day)detailed results GS-US-540-5773 (Goldman), 2020 1.46 [0.95; 2.23]
GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53]
GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09]
1.27 [1.01 ; 1.61 ] GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 0% 1,181 moderate not evaluable clinical improvement (time to event analysis only)detailed results GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02]
GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44]
GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42]
1.03 [0.81 ; 1.30 ] GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 69% 1,193 moderate not evaluable mechanical ventilationdetailed results GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30]
GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45]
0.20 [0.03 ; 1.16 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 2 0% 784 moderate not evaluable recoverydetailed results GS-US-540-5773 (Goldman), 2020 0.81 [0.64; 1.03]
GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37]
GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45]
1.03 [0.83 ; 1.28 ] GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 66% 1,193 moderate not evaluable serious adverse eventsdetailed results GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23]
GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14]
0.53 [0.30 ; 0.94 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 2 0% 784 moderate not evaluable adverse eventsdetailed results GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42]
GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80]
1.40 [1.05 ; 1.87 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 2 4% 784 moderate not evaluable serious adverse events (SAE), anydetailed results GS-US-540-5773 (Goldman), 2020 0.50 [0.32; 0.79]
0.50 [0.32 ; 0.79 ] GS-US-540-5773 (Goldman), 2020 1 0% 397 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-08-20 21:41 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 90
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290